Igea Med
On 18 December 2020, Igea Med S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 22 December 2020.
Integrae SIM acted as Nomad and Global Coordinator.
The equivalent of the placement of a total of 259,000 shares and at the start date of the negotiations on AIM Italia PRO, the share capital of Igeamed S.p.A. will be represented by a total of 2,259,000 ordinary shares with a float of 11.47% for a planned capitalization equal to € 3,388,500.
The enterprise. Igeamed, a company of the Igeam Group, operates in the market of medicine for companies and provides companies with integrated consulting and engineering services for risk management and human resources. Igeamed, which operates entirely in Italy through a capillary structure with four operational headquarters throughout the country and, in particular, in Bari, Rome, Ravenna, and Milan, aims to promote corporate healthcare, representing the ideal partner to address the new needs of companies increasingly oriented towards social responsibility and the overall well-being of employees and the company system as a whole.
Ultima Ricerca Igea Med
BREAKING NEWS| In its press release dated July 30, 2026, Siav SpA Società Benefit, Italy’s leading provider of Enterprise Content Management and Business Process Outsourcing solutions, announced the completion of the acquisition of 100.0% of the share capital of IT Consult S.r.l., an Italian software company specializing in proprietary solutions for document management, digital processes, and cloud services. The transaction was completed following the fulfillment of all contractual conditions precedent. The total consideration amounts to approximately € 3.40 million, structured as 60.0% in cash and 40.0% through a reserved capital increase. The cash consideration will be paid in three equal installments, each representing 20.0% of the purchase price: the first installment was paid at closing, while the remaining two will be settled by December 31, 2026, and March 31, 2027, respectively. The equity component was settled on the date of the announcement through the full subscription of the reserved capital increase allocated pro rata to the selling shareholders. The capital increase, approved by the Board of Directors on July 23, 2026, under the partial exercise of the authority granted by the Extraordinary Shareholders’ Meeting, involved the issuance of 480,984 new ordinary shares, with no nominal value, at a subscription price of € 2.81 per share, for a total value of approximately € 1.35 million. In addition, the agreement includes an earn-out mechanism of up to € 1.00 million, linked to the adjusted EBITDA achieved by IT Consult during the 2026 and 2027 financial years. Following the closing, the new Board of Directors of IT Consult consists of Nicola Voltan as Chairman, Giovanni Marrè as Chief Executive Officer, and Daniele Boggian as Director. From a strategic perspective, the acquisition is fully aligned with Siav’s external growth strategy and forms part of a broader organizational and managerial transformation. The integration of technological capabilities complementary to those already within the Group and the expansion of its product offering are expected to support future growth opportunities. Furthermore, the acquisition is intended to strengthen Siav’s positioning in strategically important markets, create new commercial opportunities, and enhance the quality and predictability of revenues, while ensuring business continuity and preserving the valuable know-how developed by IT Consult over the years. In light of the information disclosed in the press release, we confirm our recommendation: target price € 5.70, rating BUY, risk Medium. |
